Home » Stocks » BIO

Bio-Rad Laboratories, Inc. (BIO)

Class A Shares
Stock Price: $549.60 USD -7.68 (-1.38%)
Updated December 2, 4:02 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 16.43B
Revenue (ttm) 2.38B
Net Income (ttm) 3.52B
Shares Out 29.72M
EPS (ttm) 116.69
PE Ratio 4.71
Forward PE 45.25
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 2
Last Price $549.60
Previous Close $557.28
Change ($) -7.68
Change (%) -1.38%
Day's Open 557.92
Day's Range 543.16 - 557.92
Day's Volume 248,473
52-Week Range 320.01 - 643.45

More Stats

Market Cap 16.43B
Enterprise Value 15.91B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 29.72M
Float n/a
EPS (basic) 118.31
EPS (diluted) 116.69
FCF / Share 12.42
Dividend n/a
Dividend Yield n/a
Earnings Yield 21.23%
FCF Yield 2.25%
Payout Ratio n/a
Shares Short 387,584
Short Ratio 2.48
Short % of Float n/a
Beta 1.00
PE Ratio 4.71
Forward PE 45.25
P/FCF Ratio 44.50
PS Ratio 6.90
PB Ratio 1.81
Revenue 2.38B
Operating Income 294.92M
Net Income 3.52B
Free Cash Flow 369.21M
Net Cash 514.58M
Net Cash / Share 17.21
Gross Margin 53.00%
Operating Margin 12.39%
Profit Margin 147.90%
FCF Margin 15.51%
ROA 2.11%
ROE 50.45%
ROIC 54.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (5)

Buy 4
Overweight 0
Hold 0
Underweight 1
Sell 0

Analyst Consensus: Buy

Price Target

$658.75*
(19.86% upside)
Low
650
Current: $549.60
High
675
Target: 658.75
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue2,3122,2892,1602,0682,0192,1752,1332,0692,0741,927
Revenue Growth0.97%5.98%4.45%2.41%-7.15%1.99%3.07%-0.21%7.6%-
Gross Profit1,2571,2231,1881,1381,1221,1791,1781,1551,1791,091
Operating Income230-10311955.72167150169264305284
Net Income1,75936612226.0010988.8577.79165179185
Shares Outstanding29.8429.8429.6629.4429.1928.8828.5928.2928.0327.67
Earnings Per Share58.2712.104.070.883.713.052.695.786.296.59
EPS Growth381.57%197.3%362.5%-76.28%21.64%13.38%-53.46%-8.11%-4.55%-
Operating Cash Flow458285104216186273169266263226
Capital Expenditures-98.40-126-111-141-112-121-105-137-103-87.26
Free Cash Flow359160-7.1175.0374.2915363.69130160139
Cash & Equivalents1,1208507618447906986099218131,032
Total Debt651439435435434436437734733964
Net Cash / Debt46941132640935626217218780.6067.33
Assets8,0095,6114,2733,8513,7103,3413,3893,4443,0973,063
Liabilities2,2541,5911,3431,2711,2191,1561,2021,4281,3521,522
Book Value5,7554,0202,9302,5792,4912,1852,1872,0151,7441,537
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Bio-Rad Laboratories, Inc.
Country United States
Employees 8,000
CEO Norman Schwartz

Stock Information

Ticker Symbol BIO
Stock Exchange NYSE
Share Class Class A Shares
Sector Healthcare
Industry Medical Devices
Unique Identifier NYSE: BIO

Description

Bio-Rad Laboratories develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the United States, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.